Articles tagged "Viral therapy"

2021 American Transplant Congress
Transplanting Hepatitis C Infected Organs Into Uninfected Recipients: A Pharmacy Perspective
M. L. Holt, A. James, K. Gutierrez, T. Sparkman, J. Banbury, D. Jones
University of Alabama at Birmingham Hospital, Birmingham, AL
*Purpose: Due to direct acting antivirals (DAAs), hepatitis C virus (HCV) positive patients are now resources for organ transplantation in HCV negative recipients. Our institution…
2021 American Transplant Congress
The Use of Hcv Nat+ Organs in Hcv Negative Recipients with On-site Specialty Pharmacy Services: A Win for the Patient, the Transplant Center, and Society?
M. Person, N. Patel, W. Simerlein, H. Meadows, D. DuBay, D. Taber
Medical University of South Carolina, Charleston, SC
*Purpose: Use of HCV AB positive organs (HCV AB+) with active viremia (NAT+) relies on appropriate and timely use of direct acting antiviral therapies (DAA).…
2021 American Transplant Congress
Influence of Immunosuppressant Management on Mortality in Kidney Transplant Recipients Hospitalized with COVID-19
Y. Fenig, A. Santeusanio, M. Menon, C. Liu, M. Rana, R. Shapiro
Mount Sinai Hospital, New York, NY
*Purpose: Kidney transplant recipients are thought to be at high risk for mortality from COVID-19 due to the necessity for chronic immunosuppressive therapy to prevent…
2021 American Transplant Congress
Current Practices for Management and Treatment of COVID-19 in Immunocompromised Adults: A Survey of Institutions
H. H. Nam¹, S. Aslam², O. Beaird³, G. Forrest⁴, M. Fung⁵, A. Limaye⁶, A. Multani³, J. Nelson⁷, R. Rakita⁶, L. Strasfeld⁸, J. Schaenman³
¹Medicine, University of California - Irvine, Orange, CA, ²Division of Infectious Diseases and Global Public Health, University of California - San Diego, San Diego, CA, ³Medicine, University of California - Los Angeles, Los Angeles, CA, ⁴Medicine, Rush University, Chicago, IL, ⁵Medicine, University of California - San Francisco, San Francisco, CA, ⁶Medicine, University of Washington, Seattle, WA, ⁷Medicine, Stanford University, Palo Alto, CA, ⁸Medicine, Oregon Health and Science University, Portland, OR
*Purpose: The optimal testing strategy for solid organ transplantation (SOT) donor and recipient evaluation, as well as treatment for COVID-19 is unknown. We assessed the…
2021 American Transplant Congress
Delayed Valganciclovir Initiation and the Incidence of Cytomegalovirus Infection in Liver Transplant Recipients
S. Shaikh, P. Kawewat-Ho, Y. Genyk, L. Sher, J. Kahn, L. Rivera
Keck Medical Center of USC, Los Angeles, CA
*Purpose: Opportunistic infections remain a significant burden after liver transplantation, particularly cytomegalovirus (CMV) infection. With the use of valganciclovir (VGCV), the incidence of CMV infection…
2021 American Transplant Congress
Clinical Characteristics, Risk Factors and Outcomes of Norovirus Infection in Renal Transplant Patients: A Retrospective Single Center Study
T. Brooks¹, T. Crilley¹, B. Gaglani², N. Jakharia²
¹Department of Internal Medicine, Wake Forest University Baptist Medical Center, Winston Salem, NC, ²Division of Infectious Diseases, Wake Forest University Baptist Medical Center, Winston Salem, NC
*Purpose: Norovirus gastrointestinal infection has been identified as a cause of significant morbidity among immunocompromised hosts, particularly hematopoietic stem cell transplant (HSCT) and solid organ…
2020 American Transplant Congress
Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys
V. S. Potluri¹, F. Naqvi², P. Reese¹, M. Shah¹, D. Brown², S. Prenner¹, A. Loupy³, A. Woodards¹, P. Abt¹, E. Blumberg¹, J. Trofe-Clark¹, D. Segev², R. Bloom¹, D. Sawinski¹, C. Durand², P. Porrett¹, M. Levine¹, D. Goldberg⁴, N. Desai²
¹University of Pennsylvania, Philadelphia, PA, ²Johns Hopkins, Baltimore, MD, ³Paris Transplant Group, Paris, France, ⁴University of Miami, Miami, FL
*Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…
2020 American Transplant Congress
Access to Direct Acting Antiviral Therapy for Recipients of Solid Organs from Hepatitis C Viremic Donors
C. Edmonds, A. Carver, J. DeClercq, L. Choi, M. Peter, R. Forbes, B. Concepcion, K. Schlendorf, R. Perri
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Emerging data supports transplantation of organs from hepatitis C-positive (HCV) donors to expand the donor pool, but access to direct acting antivirals (DAAs) to…
2020 American Transplant Congress
Pharmacy Led Initiatives for Treatment of Transplant Recipients of Hepatitis C Viremic Donors in a High Volume Transplant Center
H. Berry, J. Byrns, L. Crona, T. Capes, J. M. Steinbrink, E. K. Maziarz, C. R. Wolfe
Duke University Medical Center, Durham, NC
*Purpose: We describe a multidisciplinary workflow for initiation of hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies post-transplant in the outpatient setting of a high…
2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
S. Bova¹, A. Cameron¹, C. Durand¹, J. Katzianer², M. LeGrand², L. Boyer¹, J. Glorioso³, L. P. Toman¹
¹The Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins Home Care Group, Baltimore, MD, ³Thomas Jefferson Univeristy Hospital, Philadelphia, PA
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…